Emotional Intelligence Ventures (Ei.Ventures) announced that it’s raising $50 million via a ‘regulation A+’ public stock offering. The funding will take it from being a subsidiary of Orthogonal Thinker to a public company. The announcement was made in March 2021, with fundraising still ongoing in February 2022.
Emotional Intelligence Ventures (Ei.Ventures or Ei), Inc, the leader in all-natural psychedelic medicine development, today announced that it has been qualified by the Securities and Exchange Commission (SEC) to list a $50 million exempt public stock offering using the Regulation A+ Tier 2 framework. This is only the second public stock offering in the psychedelic medicine space in the U.S. and the first for a company developing products only from all-natural botanical material. A Regulation A+ offering allows for retail investors to invest in pre-public and private companies. The net proceeds of the offering will be used to accelerate the development and distribution of Ei’s medicinal and functional mushroom product lines.
Ei.Ventures is launching this offering as the public needs real access to novel therapies that can reverse, heal, and treat chronic mental health disorders. Ei is the only company poised to bring botanical psychedelic therapies, functional plant medicines, and integrative technology to the market in an acceptable time frame of under 2 years. Due to Covid, lockdowns, and the economic impact of the pandemic, the state of Americans’ mental health has declined significantly over the past year. Ei.Ventures’ solutions need to come to the market as soon as possible and Ei wants to give the retail-investing public a chance to participate in the upside potential of this exciting new field of healthcare.
“While we have raised money with our friends & family and private placement raises, we are so committed to the unaccredited investor, that we’ve engaged with the SEC for a Reg A+,” said David Nikzad, founder and CEO of Ei.Ventures. “As I’ve been fortunate to invest early in numerous companies like Airbnb, Betterment, and Vidyard, and three equity crowdfunding platforms (WeFunder, RealCrowd, Republic), I’m really passionate about democratizing investment opportunities so any investor can reap the rewards, and take all of the risks of early investment in game-changing companies.”
“We believe that this offering may be the first time an all-natural psychedelic medicine project received approval to access the public U.S. markets and we are excited to continue to pursue our capital markets pathway in the U.S. and Canada,” Nikzad continued. “This can potentially set a precedent for others in the industry.”
Companies Featured
EI.VenturesEI.Ventures is a subsidiary of Orthogonal Thinker that is currently raising $50 million. Though scant on details, the company is developing Psilly (whole-plant botanical psilocybin-based formulation) and has (presumably) launched a consumer non-psychedelic mushroom brand 'Mana'.